



## Grant of Options

February 15, 2018 12:00 PM EST

Released : February 15, 2018 07:00

RNS Number : 9370E

MaxCyte, Inc.

15 February 2018

### MaxCyte, Inc.

("MaxCyte" or the "Company")

### Grant of Options

**Maryland, USA, 15 February 2018** - MaxCyte (LSE: MXCT, MXCR) the global cell-based medicines and technology company, announces that it granted options, effective February 12, 2018, over a total of 40,900 options of its common stock in the Company ("Common Stock") to Richard Douglas, Non-Executive Director of the Company ("Option Grant").

The Option Grant vests ratably on a monthly basis following grant over 48 months. The Option Grant has an exercise period of 10 years from date of grant, at which time they will expire. The Option Grant is effective February 12, 2018, at an exercise price of 251.00p per option.

**This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").**

#### NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

<b>1</b>	<b>Details of the person discharging managerial responsibilities/person closely associated</b>	
a)	Name	Richard Douglas
<b>2</b>	<b>Reason for the notification</b>	

a)	Position/status	Non-Executive Director and PDMR	
b)	Initial notification/Amendment	Initial notification	
<b>3</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>		
a)	Name	MaxCyte, Inc.	
b)	LEI	54930053YHXULRFCU991	
<b>4</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>		
a)	Description of the financial instrument, type of instrument	Grant of options over Share of Common Stock	
b)	Identification Code	US57777K1060	
c)	Nature of the transaction	Grant of options to a PDMR	
d)	Price(s) and volume(s)	Price(s)	Volume(s)
		251.00 pence	40,900
e)	Aggregated information - Aggregated volume - Price	N/A (Single transaction)	
f)	Date of the transaction	12 February 2018	
g)	Place of the transaction	Outside a trading venue	

**For further information, please contact:**

**MaxCyte Inc.**

Doug Doerfler, Chief Executive Officer

+1 301 944 1660

Ron Holtz, Chief Financial Officer

***Nominated Adviser and Broker***

**Panmure Gordon**

Freddy Crossley (Corporate Finance)  
Ryan McCarthy  
Tom Salvesen (Corporate Broking)

+44 (0) 20 7886 2500

***Financial PR Adviser***

**Consilium Strategic Communications**

Mary-Jane Elliott  
Chris Welsh  
Suki Virji

+44 (0)203 709 5700

[maxcyte@consilium-comms.com](mailto:maxcyte@consilium-comms.com)

**About MaxCyte**

MaxCyte (LSE: MXCT, MXCR) is a US-based global company driving the acceleration of the discovery, development, manufacturing and commercialization of next-generation, cell-based medicines. The Company provides its patented, high-performance cell engineering enabling technology to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing, and cell therapy, including gene editing and immuno-oncology. With its robust delivery technology, MaxCyte's team of scientific experts helps its partners to unlock their product potential and solve problems. This technology allows for the engineering of nearly all cell types, including human primary cells, with any molecule, at any scale. It also provides a high degree of consistency and minimal cell disturbance, thereby facilitating rapid, large-scale, clinical and commercial grade cell engineering in a non-viral system and with low-toxicity concerns. The Company's cell-engineering enabling technology is FDA-accredited, providing MaxCyte's customers and partners with an established regulatory path to commercialize cell-based medicines. MaxCyte is also developing CARMA, its proprietary, breakthrough platform in immuno-oncology, to rapidly manufacture CAR therapies for a broad range of cancer indications, including solid tumours where existing CAR-T approaches face significant challenges. For more information, visit <http://www.maxcyte.com/>.

This information is provided by RNS  
The company news service from the London Stock Exchange

END

DSHEAFALFLPPEAF